Medical University of Havana, Havana, Cuba.
MEDICC Rev. 2021 Apr;23(2):21. doi: 10.37757/MR2021.V23.N2.7. Epub 2021 Apr 30.
Disease and deaths from HIV/AIDS have decreased since antiretroviral treatment was introduced in 1996. Since 2005, as treatment availability has increased worldwide, deaths from HIV/AIDS have declined 48%. As of November 2019, 26,952 cases have been reported in Cuba, of which 5159 (19.1%) are deceased. The country has experienced a reduction in mortality rates since 2002, when antiretroviral treatment became available. Although there are clearly benefits to treatment, it is important to understand antiretroviral safety profiles as their toxicity may lower treatment adherence.
Describe adverse reactions attributable to antiretrovirals used in Cuban patients living with HIV/AIDS.
I studied notifications of adverse reactions to antiretrovirals used in Cuban patients with HIV/AIDS from January 2003 to December 2017. The sample consisted of 352 notifications in the National Pharmacovigilance Database regarding adverse reactions attributed to antiretrovirals. The variables considered were sex, notification year, antiretroviral drug, and number, type, frequency and severity of adverse reactions, whether or not they were preventable, and the reasons for categorizing them as they were.
Antiretrovirals reported an average adverse reaction rate of 2.1 per million population per year, representing 24.2% of adverse reactions produced by the antiviral drug group in that period. Adult males represented 75% (264/352) of patients who had adverse reactions to antiretrovirals. Most adverse reactions were in response to nevirapine (29.0%; 102/352) and zidovudine (26.7%; 94/352). The most frequent reactions were hypersensitivity (24.4%; 86/352), digestive disorders (15.9%; 56/352) and anemia (15.6%; 55/352). Reactions were common (62.5%; 220/352) and moderate in severity (70.4%; 248/352). Preventable reactions made up 52.6% (185/352) of adverse reactions. Of preventable reactions, 68.1% (126/185) were associated with drug interactions and 16.2% (30/185) with improper dosage or prescription errors.
Adverse reactions to antiretrovirals in Cuban patients are common and moderate in severity. The drug with the most notifications was nevirapine, and the most common adverse reaction was hypersensitivity. More than half of adverse reactions are considered preventable, and their main causes are prescription errors.
自 1996 年引入抗逆转录病毒治疗以来,艾滋病毒/艾滋病的疾病和死亡人数有所下降。自 2005 年以来,随着全球治疗方法的普及,艾滋病毒/艾滋病死亡人数下降了 48%。截至 2019 年 11 月,古巴报告了 26952 例病例,其中 5159 例(19.1%)死亡。自 2002 年抗逆转录病毒治疗可用以来,该国的死亡率有所下降。尽管治疗显然有好处,但了解抗逆转录病毒的安全性概况很重要,因为它们的毒性可能会降低治疗的依从性。
描述古巴艾滋病毒/艾滋病患者使用抗逆转录病毒药物引起的不良反应。
我研究了 2003 年 1 月至 2017 年 12 月期间古巴艾滋病毒/艾滋病患者使用抗逆转录病毒药物引起的不良反应通知。该样本包括国家药物警戒数据库中 352 份关于抗逆转录病毒药物不良反应的通知。考虑的变量包括性别、通知年份、抗逆转录病毒药物以及不良反应的数量、类型、频率和严重程度、是否可预防以及将其分类的原因。
抗逆转录病毒药物的不良反应报告发生率平均为每百万人口每年 2.1 例,占同期抗病毒药物组不良反应的 24.2%。成年男性占报告抗逆转录病毒药物不良反应的患者的 75%(264/352)。大多数不良反应是由于奈韦拉平(29.0%;102/352)和齐多夫定(26.7%;94/352)引起的。最常见的反应是过敏(24.4%;86/352)、消化系统疾病(15.9%;56/352)和贫血(15.6%;55/352)。反应很常见(62.5%;220/352),且严重程度为中度(70.4%;248/352)。可预防的反应占不良反应的 52.6%(185/352)。可预防的反应中,68.1%(126/185)与药物相互作用有关,16.2%(30/185)与剂量不当或处方错误有关。
古巴患者使用抗逆转录病毒药物引起的不良反应很常见,且严重程度为中度。通知数量最多的药物是奈韦拉平,最常见的不良反应是过敏。超过一半的不良反应被认为是可以预防的,其主要原因是处方错误。